Efficacy of @entity906 for the relief of XXXX and @entity901 -induced acute @entity2359 : a single-center retrospective case-control study.

@entity901 @entity1 @entity137 @entity308 @entity390 @entity16 @entity391 @entity1395 @entity3907 @entity148 @entity158 @entity906 @entity694 @entity9 @entity2359
BACKGROUND: @entity901 and @entity3907 -induced @entity137 is dose-limiting and mostly presents with acute symptoms that affect the activities of daily living and overall quality of life. The objective of the present study is to assess the relief of acute @entity16 with @entity906 treatment during the chemotherapy period. @entity1 AND METHODS: In this retrospective case-control study, from January 2010 to February 2015, @entity1 who experienced treatment with @entity901 and @entity3907 -induced acute @entity2359 were evaluated according to the NCI-CTCAE v. 4.03 grading scale. @entity2359 was evaluated using a numeric rating scale (NRS) for @entity158 intensity and experienced relief under the treatment of @entity906 and using a @entity9 symptom inventory scale (NPSI) for the style of complaints. @entity1 who were diagnosed as mildly depressed according to the HOST @entity148 and @entity308 scale and who had grade 1 to 3 sensory @entity2359 based on the NCI-CTCAE v. 4.03 grading scale, and who also reported >= 4/10 on a NRS were eligible. The primary end point was the rate of more than 75  % symptomatic relief under @entity906 treatment. RESULTS: Two hundred six @entity1 were included (82  % female, median age: 52.7  years). Most @entity1 had breast, gynecologic, and @entity694 (93.4  %). Ninety-one @entity1 who received @entity906 and 115 @entity1 as the control group were assessed for @entity2359 every 3  weeks. Based on the NRS, a rate of more than 75  % symptomatic relief was 53.5, 58.3, and45.2  % in @entity906 arm versus 0, 0, and 0  % in the control arm in the first, second, and third visits, respectively. Side-effects of @entity906 (n   =   7) were grade 1-2 @entity390 / @entity391 (3.2  %) and @entity1395 /somnolence (3.2  %) without grade 3-4 events. CONCLUSION: @entity906 has a significant clinical activity against @entity3907 - @entity901 -induced acute @entity137 .
